To The Moon

$Alumis Inc.(ALMS)$ $Bristol-Myers Squibb(BMY)$ $Arcutis Biotherapeutics Inc.(ARQT)$ 🚀🧬📊 $ALMS Repriced, Not Rallied: Phase 3 Dominance Ignites Volatility Expansion and Price Discovery 📊🧬🚀 I’m treating today’s move in Alumis Inc ($ALMS) as a live, in-session repricing event, not a completed story. With the market still open, price, volume, and flow continue to confirm a regime shift rather than a one-day headline reaction. $ALMS is up +106.5% to ~$17.16 after its lead oral TYK2 inhibitor delivered a decisive Phase 3 outcome in the ONWARD1 and ONWARD2 plaque psoriasis trials. Around 65% PASI 90 and more than 40% PASI 100 at Week 24, with rapid onset and a clean safety profile, places this asset firmly in the commercially relevant tier of psoriasis therapies. Beating placebo and apremilast reframes valuation expectations immediately, while discovery is still unfolding. What matters now is how the market is contextualising the data. Institutions are already benchmarking this profile against Bristol Myers Squibb ($BMY)’s approved TYK2 therapy, which pulls $ALMS into a validated, multi-billion-dollar therapeutic lane rather than a speculative corner of biotech. That comparison alone changes how duration capital approaches this move. At the same time, momentum traders are naturally grouping $ALMS alongside Arcutis Biotherapeutics ($ARQT), a high-engagement dermatology biotech that the Tiger ecosystem already trades aggressively around catalysts. That pairing keeps $ALMS circulating inside the most active psoriasis and immunology clusters while the session is still live. Technically, the structure remains clean. Higher timeframe volatility compression resolved into an impulsive expansion that cleared stacked EMAs and blew out Bollinger and Keltner bands. Intraday price surged, then transitioned into controlled consolidation above VWAP rather than fading. SSR has been triggered, volume remains elevated, and supply has been notably absent on pullbacks. Options flow continues to validate the repricing. Volume has already printed roughly 39x average, with heavy interest in Jan 2026 $21 calls, signalling longer-dated positioning rather than same-day speculation. From a live structure standpoint, my focus is clear. $20.00 is the immediate resistance and psychological inflection. Acceptance above that level opens a path toward $22.50 and then $25.00, which align with higher timeframe reference levels. On the downside, I want to see $19.20 hold as support. As long as that zone is defended, price discovery remains intact. This is not just solid news. This is a name transitioning from dormant to active, from compressed to expansive, and from ignored to institutionally relevant, in real time. 📢 Don’t miss out! Like, Repost and Follow me for exclusive setups, cutting-edge trends, and insights that move markets 🚀📈 I’m obsessed with hunting down the next big movers and sharing strategies that crush it. Let’s outsmart the market and stack those gains together! 🍀 Trade like a boss! Happy trading ahead, Cheers, BC 📈🚀🍀🍀🍀 @Tiger_comments @TigerStars @TigerPicks @TigerObserver @Daily_Discussion @TigerWire